Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105092 · ClinicalTrials.gov registry record · Phase 2
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT00105092 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants, below the 234-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00105092, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Conditions Studied
Interventions
- DRUG Enzastaurin HCL
Study Locations (3)
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Tampa
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Nashville
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105092
The ClinicalTrials.gov registry entry for NCT00105092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (79% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Enzastaurin HCL is the first listed.
NCT00105092 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT00105092 about?
NCT00105092 is a clinical study titled "Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.". Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
What is the current status of trial NCT00105092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00105092 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT00105092?
The interventions under investigation include: Enzastaurin HCL (DRUG).
Who is sponsoring clinical trial NCT00105092?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105092 being conducted?
This trial has 3 study locations across Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
-
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.